Candel Therapeutics (CADL) Invested Capital (2020 - 2023)
Historic Invested Capital for Candel Therapeutics (CADL) over the last 4 years, with Q3 2023 value amounting to $29.1 million.
- Candel Therapeutics' Invested Capital fell 5962.4% to $29.1 million in Q3 2023 from the same period last year, while for Sep 2023 it was $29.1 million, marking a year-over-year decrease of 5962.4%. This contributed to the annual value of $67.7 million for FY2022, which is 466.33% up from last year.
- According to the latest figures from Q3 2023, Candel Therapeutics' Invested Capital is $29.1 million, which was down 5962.4% from $34.4 million recorded in Q2 2023.
- In the past 5 years, Candel Therapeutics' Invested Capital ranged from a high of $83.8 million in Q1 2022 and a low of -$42.7 million during Q2 2021
- Its 4-year average for Invested Capital is $42.8 million, with a median of $63.5 million in 2021.
- As far as peak fluctuations go, Candel Therapeutics' Invested Capital soared by 38032.84% in 2021, and later plummeted by 5962.4% in 2023.
- Candel Therapeutics' Invested Capital (Quarter) stood at -$23.1 million in 2020, then skyrocketed by 380.33% to $64.7 million in 2021, then rose by 4.66% to $67.7 million in 2022, then tumbled by 56.99% to $29.1 million in 2023.
- Its Invested Capital was $29.1 million in Q3 2023, compared to $34.4 million in Q2 2023 and $40.9 million in Q1 2023.